RNS Number: 1971U

**EKF Diagnostics Holdings PLC** 

21 December 2012

**EKF Diagnostics** 

## **Holdings plc**

("EKF" or the "Company")

## **Directors' Exercise of Options**

EKF (AIM: EKF), the growing in-vitro diagnostics company, announces that on 18 December 2012 it received notification of the exercise of options on 18 December 2012 over 500,000 Ordinary Shares of one pence each in the Company (the "Ordinary Shares") by Gordon Hall (Non-Executive Director) all at an exercise price of 20 pence per Ordinary Share.

These options were granted to Mr Hall as part of the Company's Long Term Incentive Plan and he does not have any immediate plans to sell the shares.

Application will be made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 500,000 new Ordinary Shares to AIM will become effective on, or around, 4 January 2012.

After the exercise of options, and the Admission of the new Ordinary Shares to AIM, Gordon Hall will hold 839,282 Ordinary Shares representing 0.3 per cent. of the Company's issued share capital.

## **Enquiries:**

**EKF Diagnostics Holdings plc**David Evans, Executive Chairman Julian Baines, CEO

**Canaccord Genuity Limited** Lucy Tilley / Henry Fitzgerald-O'Connor

Walbrook PR Limited

Walbrook PR Limited
Paul McManus

**Tel: 029 2071 0570** Mob: 07740 084 452 Mob: 07788 420 859

Tel: 020 7523 8000

**Tel: 020 7933 8780**Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

## About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for EUR14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Company has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of GBP5.41m), Argutus Medical Limited (acquired in December

2010 for GBP2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo\_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS
The company news service from the London Stock Exchange

**END** 

MSCTBBATMBATBTT admin Directors' Exercise of Options 20585205 A Fri, 12/21/2012 - 15:53 Company Announcement - General EKF